ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Swedish Orphan Biovitrum clinical trials

Also known as Sobi.

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 137 studies whose lead sponsor is Swedish Orphan Biovitrum or one of 2 companies grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 9, 2026.

Our grouping of 4 registry names, not the registry’s. See them and correct one ↓

Compare Swedish Orphan Biovitrum with Novo Nordisk and R-Pharm →

Pipeline: 7 programs

Each counted once: 7 with a study Swedish Orphan Biovitrum leads registered in the last two years.

  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 2 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Swedish Orphan Biovitrum’s own registered studies; Swedish Orphan Biovitrum’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Swedish Orphan Biovitrum’s studies test, most open studies first — 36 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 36; every drug is on its own page, and each page lists its sponsors.

Coming up

4 of Swedish Orphan Biovitrum’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 1D
  3. J’27
  4. F
  5. 2M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add all 4 to your calendar (.ics) → With an account.

All 137 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now64%Recruiting 4 · Not yet recruiting 2
  • Under way, not recruiting75%
  • Completed9166%
  • Stopped early3324%Terminated 23 · Withdrawn 10

Phase

Where

  • United States70
  • Italy40
  • Germany36
  • United Kingdom34
  • France34
  • Spain28

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 1020
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 526

By the year each study started; 26 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Swedish Orphan Biovitrum.

  • Swedish Orphan Biovitrum
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    82 studies
  • CTI BioPharma
    Acquired — became part of Swedish Orphan Biovitrum, Jun 24, 2023 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    38 studies →
  • Arthrosi Therapeutics
    Acquired — became part of Swedish Orphan Biovitrum, Feb 9, 2026 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    10 studies →
  • Sobi, Inc.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies

Focus areas

Conditions Swedish Orphan Biovitrum leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 137. Browse all 137 →